On Mar. 30, 2020, Altimmune announced that it had launched a collaboration with the University of Alabama at Birmingham (UAB) on the development of its single-dose, intranasal COVID-19 vaccine, named AdCOVID. NasoShield is being developed under a $133.7 million contract with Biomedical Advanced Research and Development Authority (BARDA).